A new review highlights lentiviral vectors’ expanding role in gene‑therapy design, describing engineered constructs and delivery advances that improve transduction efficiency, tropism, and safety profiling. The analysis by Kaiser, Rouchka, and Smith synthesizes recent progress in vector pseudotyping, promoter design, and manufacturing improvements that are accelerating clinical translation. Lentiviral vectors are virus‑derived delivery vehicles used to insert genetic material into host cells; they are widely used in ex vivo cell therapies and emerging in in vivo approaches. Improved vector design reduces off‑target effects and insertional risk, which regulators and developers cite as central to next‑generation gene therapies.